Oral Drug Delivery Market Size, Share, Growth Report 2030

Oral Drug Delivery Market Size

The global oral drug delivery market size was USD 119.92 billion in 2020 and is expected to reach USD 220.32 billion by 2028, growing at a CAGR of 7.9% from 2021 to 2028.Request Free Sample

Oral drug delivery is the most conducive and favored route of drug administration due to factors such as least sterility constraints, patient compliance, flexibility in the design of the dosage form, ease of production, and cost effectiveness. The oral route of drug administration has developed over the last few years with the help of technologies and clinical trials. The market is primarily driven by the increase in the prevalence of chronic diseases, which has led to an increase in the demand for oral drug delivery systems for the treatment of such diseases. To maintain the efficiency of oral drug delivery, there has been increased utilization of nanocarriers for oral drug delivery. Recent developments such as dome tablets, intestinal patches, polymer nanosystems, and dual drug tablets have been revolutionizing the field.

COVID-19 Impact Analysis

The COVID-19 pandemic has brought some serious medical, social, and economic challenges. The supply chain ecosystem has been disrupted, which has led to a shortage of production. Restricted lockdowns and closed international borders have created transportation barriers, resulting in a shortage of raw materials.Also, the social distancing norms have led to a decrease in the number of employees working in the industry for production, thus affecting the production of oral drugs.

Growth Factors

The rising prevalence of chronic diseases has been driving the oral drug delivery market. The growth in research and development by various pharmaceutical companies has boosted the market. Among the drug delivery routes, oral drug delivery is the most preferred one in various therapeutic areas, which is also the reason to boost this market.

The growth in the biologics market and the increasing penetration of health insurance will boost market growth. Also, an increasing number of pharmaceutical companies have been driving the market. The technological developments and the new product launches in the market have also accelerated the overall drug delivery market.

Report Scope :

Oral Drug Delivery Market Segment Analysis By Type

This is due to the fact that controlled drug delivery has advantages such as the total dose is low, it has reduced dosing frequency, is better accepted by patients and is more complaint, has more uniform drug effect and has improved efficacy/safety ratio. It is the method that delivers the drug at a predetermined rate, either systematically or locally, for a specified period of time.

End Users Analysis

This is primarily due to factors such as the large number of inpatient and outpatient hospital visits for treatment.The high number of inpatients and outpatients visiting the hospitals increases the requirement for a huge number of drugs to be administered to the patients in the hospitals. As a result, hospitals are the most common end users of oral drug delivery systems.

These centers are 45–60% less expensive than hospitals, thus providing a significant savings to the patients. Also, the outcomes found are better and infection rates are lower than in hospitals. Ambulatory surgical centers provide services 24 hours a day, seven days a week and can handle any type of illness, surgery, or emergency. 

Oral Drug Delivery Market Share

Request Free Sample

Product Analysis

This is due to factors such as new production techniques introduced to produce the syrups, their availability in a variety of compositions for the consumers, and their increased effectiveness in treating infections and diseases. The content of the syrups provides useful vitamins, rich minerals, and proteins required for the overall development of the patients. Thus, the health benefits and the wide availability are driving this segment in the oral drug delivery market.

Regional Analysis

North America held a share of 39% in 2020. This is due to factors such as the presence of a large number of pharmaceutical companies, a robust pharmaceutical industry, drug delivery technology providers, and the rising number of collaborations between technology providers and pharmaceutical companies. Also, the increased demand for self-administration and home healthcare devices, transdermal patches and transmucosal systems for chronic diseases, and increasing applications of inhalers have boosted the market in this region.

Asia-Pacific is expected to have a CAGR of 9.3% from 2021 to 2028. This is due to factors such as western market saturation and the economic downturn in the United States and Europe. In addition, factors such as the rise in disposable incomes, the increasing penetration of health insurance, the development of healthcare infrastructure, and the increase in chronic diseases are boosting the overall market in this region.

Request Free Sample

Key Market Players & Competitive Landscape

Some of the key players in the Oral Drug Delivery market include AdhexPharma, Protalix, CURE Pharamceutical, Evonik, Arx LLC, Catalent Inc., INTELGENX CORP, Assembly Biosciences Inc., Aquestive Therapeutics, Emisphere Technologies, ZIM Laboratories Limited, Adare Pharmaceuticals, Merrion Pharmaceuticals Plc, Oramed Pharmaceuticals, Samyang Corporation, Chimerix Inc., Skypepharma, Amcor Limited and Unigene Laboratories Inc. amog others.

In 2020, Novo Nordisk acquired Emisphere, a drug delivery company, on a cash-free, debt free basis, for $1.35 billion. With the acquisition Novo Nordisk obtained full access to the Eligen  SNAC technology platform thereby expanding its portfolio of oral biologic pipeline assets across therapy areas.

The Global Oral Drug Delivery Market is segmented as follows:

By Type

• Controlled Release
• Orodispersible Tablets

By End Users

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers

By Product

• Tablets
• Syrups

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa